Boston Scientific Earnings Beat Expectations. Why the Stock Is Down Sharply. -- Barrons.com

Dow Jones

Feb 04

By Nate Wolf

Shares of Boston Scientific tumbled Wednesday after the medical-device maker beat earnings expectations but offered a disappointing outlook for the current quarter.

Boston Scientific posted adjusted earnings of 80 cents a share for the fourth quarter, above analysts' consensus forecast of 78 cents, according to FactSet. Net sales totaled $5.29 billion, up 12.7% on an organic basis from last year and slightly above Wall Street's call for $5.28 billion.

The company expects 8.5% to 10% organic growth and adjusted per-share earnings of 78 cents to 80 cents in the first quarter. Analysts had been looking for 9.8% growth and adjusted earnings of 80 cents.

Boston Scientific stock dropped 8.4% in premarket trading Wednesday. The company was a Barron's stock pick in October and has since fallen 8.7% through Tuesday's close.

The guidance for the entirety of 2026 was more upbeat. Boston Scientific forecast adjusted per-share earnings of $3.43 to $3.49 and organic growth of 10% to 11% for the year. Both ranges are in line with consensus estimates.

Write to Nate Wolf at nate.wolf@barrons.com

This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

February 04, 2026 08:12 ET (13:12 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2608364226"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2608364226\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2608364226?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-04 21:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608364226","market":"us","top_or_hot":-1,"title":"Boston Scientific Earnings Beat Expectations. Why the Stock Is Down Sharply. -- Barrons.com","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Nate Wolf \n</p>\n<p>\n  Shares of Boston Scientific tumbled Wednesday after the medical-device maker beat earnings expectations but offered a disappointing outlook for the current quarter. \n</p>\n<p>\n  Boston Scientific posted adjusted earnings of 80 cents a share for the fourth quarter, above analysts' consensus forecast of 78 cents, according to FactSet. Net sales totaled $5.29 billion, up 12.7% on an organic basis from last year and slightly above Wall Street's call for $5.28 billion. \n</p>\n<p>\n  The company expects 8.5% to 10% organic growth and adjusted per-share earnings of 78 cents to 80 cents in the first quarter. Analysts had been looking for 9.8% growth and adjusted earnings of 80 cents. \n</p>\n<p>\n  Boston Scientific stock dropped 8.4% in premarket trading Wednesday. The company was a Barron's stock pick in October and has since fallen 8.7% through Tuesday's close. \n</p>\n<p>\n  The guidance for the entirety of 2026 was more upbeat. Boston Scientific forecast adjusted per-share earnings of $3.43 to $3.49 and organic growth of 10% to 11% for the year. Both ranges are in line with consensus estimates. \n</p>\n<p>\n  Write to Nate Wolf at nate.wolf@barrons.com \n</p>\n<p>\n   This content was created by Barron's, which is operated by Dow Jones &amp; Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 04, 2026 08:12 ET (13:12 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Boston Scientific Earnings Beat Expectations. Why the Stock Is Down Sharply. -- Barrons.com</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBoston Scientific Earnings Beat Expectations. Why the Stock Is Down Sharply. -- Barrons.com\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-02-04 21:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Nate Wolf \n</p>\n<p>\n  Shares of Boston Scientific tumbled Wednesday after the medical-device maker beat earnings expectations but offered a disappointing outlook for the current quarter. \n</p>\n<p>\n  Boston Scientific posted adjusted earnings of 80 cents a share for the fourth quarter, above analysts' consensus forecast of 78 cents, according to FactSet. Net sales totaled $5.29 billion, up 12.7% on an organic basis from last year and slightly above Wall Street's call for $5.28 billion. \n</p>\n<p>\n  The company expects 8.5% to 10% organic growth and adjusted per-share earnings of 78 cents to 80 cents in the first quarter. Analysts had been looking for 9.8% growth and adjusted earnings of 80 cents. \n</p>\n<p>\n  Boston Scientific stock dropped 8.4% in premarket trading Wednesday. The company was a Barron's stock pick in October and has since fallen 8.7% through Tuesday's close. \n</p>\n<p>\n  The guidance for the entirety of 2026 was more upbeat. Boston Scientific forecast adjusted per-share earnings of $3.43 to $3.49 and organic growth of 10% to 11% for the year. Both ranges are in line with consensus estimates. \n</p>\n<p>\n  Write to Nate Wolf at nate.wolf@barrons.com \n</p>\n<p>\n   This content was created by Barron's, which is operated by Dow Jones &amp; Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 04, 2026 08:12 ET (13:12 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BSX","symbol_name":"波士顿科学","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2608364226","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2608364226","pubTimestamp":1770210720,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Boston Scientific tumbled Wednesday after the medical-device maker beat earnings expectations but offered a disappointing outlook for the current quarter.Boston Scientific posted adjusted earnings of 80 cents a share for the fourth quarter, above analysts' consensus forecast of 78 cents, according to FactSet. Net sales totaled $5.29 billion, up 12.7% on an organic basis from last year and slightly above Wall Street's call for $5.28 billion.The company expects 8.5% to 10% organic growth and adjusted per-share earnings of 78 cents to 80 cents in the first quarter. Analysts had been looking for 9.8% growth and adjusted earnings of 80 cents.Boston Scientific stock dropped 8.4% in premarket trading Wednesday. The company was a Barron's stock pick in October and has since fallen 8.7% through Tuesday's close.The guidance for the entirety of 2026 was more upbeat. Boston Scientific forecast adjusted per-share earnings of $3.43 to $3.49 and organic growth of 10% to 11% for the year. Bo","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"BSX":"波士顿科学"},"translate_title":"波士顿科学公司的盈利超出预期。股票为何大幅下跌。——Barrons.com","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BSX":1.5},"content_text":"By Nate Wolf \n\n\n  Shares of Boston Scientific tumbled Wednesday after the medical-device maker beat earnings expectations but offered a disappointing outlook for the current quarter. \n\n\n  Boston Scientific posted adjusted earnings of 80 cents a share for the fourth quarter, above analysts' consensus forecast of 78 cents, according to FactSet. Net sales totaled $5.29 billion, up 12.7% on an organic basis from last year and slightly above Wall Street's call for $5.28 billion. \n\n\n  The company expects 8.5% to 10% organic growth and adjusted per-share earnings of 78 cents to 80 cents in the first quarter. Analysts had been looking for 9.8% growth and adjusted earnings of 80 cents. \n\n\n  Boston Scientific stock dropped 8.4% in premarket trading Wednesday. The company was a Barron's stock pick in October and has since fallen 8.7% through Tuesday's close. \n\n\n  The guidance for the entirety of 2026 was more upbeat. Boston Scientific forecast adjusted per-share earnings of $3.43 to $3.49 and organic growth of 10% to 11% for the year. Both ranges are in line with consensus estimates. \n\n\n  Write to Nate Wolf at nate.wolf@barrons.com \n\n\n   This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal. \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 04, 2026 08:12 ET (13:12 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}